Clinical trials
Peripheral Arterial Disease trials in Russia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 4 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2023 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Unknown status | 6 |
| Recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bayer | 4 |
| Ryazan State Medical University | 3 |
| Angiogenix | 1 |
| Artgen Biotech | 1 |
| AstraZeneca | 1 |
| CSL Behring | 1 |
| Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation | 1 |
| Cook Group Incorporated | 1 |
| Institute for Atherosclerosis Research, Russia | 1 |
| Kowa Research Institute, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peripheral Arterial Disease | 24 |
| Atherosclerosis | 6 |
| Coronary Artery Disease | 5 |
| Intermittent Claudication | 3 |
| Angina Pectoris | 2 |
| Cardiovascular Diseases | 2 |
| Chronic Limb-Threatening Ischemia | 2 |
| Heart Diseases | 2 |
| Heart Failure | 2 |
| Myocardial Infarction | 2 |
Trials
Showing 51 to 24 of 24. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.